Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Manuela Krumbholz - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Matthias Karl - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Josephine T. Tauer - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Kinder- und Jugendmedizin (Autor:in)
  • Christian Thiede - , Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav Carus Dresden (Autor:in)
  • Wolfgang Rascher - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Meinolf Suttorp - , Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Kinder- und Jugendmedizin (Autor:in)
  • Markus Metzler - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)

Abstract

Chronic myeloid leukemia (CML) is a rare disease in children and adolescents and various aspects-from molecular genesis to therapy regimen-have been taken over from studies on the more prevalent adult CML. However, differences have been observed between malignancies with identical underlying chromosomal translocations, but occurring at different age groups, suggesting some diversity in the mechanisms of formation and leukemogenesis. A multiplex long-range PCR-based assay was developed to allow fast and reliable amplification of patient-specific BCR-ABL1 fusion sequences from genomic DNA. The localization of breakpoints was analyzed with respect to distribution within the breakpoint cluster regions, sequence features, and association to repetitive elements or motifs associated with DNA recombination. The genomic fusion sites of 59 pediatric CML patients showed a bimodal breakpoint distribution in BCR that was different from the distribution in adult CML cases, but with similarities to BCR-ABL1-positive, acute lymphoblastic leukemia in adults. BCR breakpoints were found more frequently positioned within, or close to, Alu repeats than would be expected based on their overall sequence proportion. Technical aspects of the highly sensitive DNA-based quantification of residual CML cells by specific fusion sequence during tyrosine kinase inhibitor therapy are exemplified in a subcohort of pediatric CML patients.

Details

OriginalspracheEnglisch
Seiten (von - bis)1045-1053
Seitenumfang9
FachzeitschriftGenes Chromosomes and Cancer
Jahrgang51
Ausgabenummer11
PublikationsstatusVeröffentlicht - Nov. 2012
Peer-Review-StatusJa

Externe IDs

PubMed 22887688

Schlagworte

Ziele für nachhaltige Entwicklung

ASJC Scopus Sachgebiete